Article

Schwind showcases new excimer laser

Three years of research and development paid off today when Schwind eye-tech-solutions unveiled the Schwind AMARIS excimer laser to the refractive surgery community. According to CEO Rolf Schwind, it successfully combines all available state-of-the-art technologies in one single system.

Three years of research and development paid off today when Schwind eye-tech-solutions unveiled the Schwind AMARIS excimer laser to the refractive surgery community. According to CEO Rolf Schwind, it successfully combines all available state-of-the-art technologies in one single system.

Boasting a 1,050 Hz turbo eye tracker (5 D eye tracker), with a response time of less than three milliseconds, and other features, such as rotation balance, limbus tracking and static as well as dynamic cylcotorsion control, the company believes that it has produced the fastest and most accurate eye tracking system on the market.

Accuracy of ablation is governed by the system's "TotalTech Laser", which has a true pulse frequency of 500 Hz and two automatically adapted fluence values. Depending on the refraction to be corrected, approximately 80% of the corneal ablation is performed with a high fluence (high-speed) level, whilst fine correction takes place with a low fluence level. According to Schwind, one diopter of correction takes on average less than 2.5 seconds with the Schwind AMARIS, whilst the small beam diameter of 0.54 mm (FWHM) allows maximum precision and smooth treatment surfaces.

The laser's Intelligent Thermal Effect Control has been designed to provide dynamically adapted distribution of the laser pulses, thus reducing significant heating of the cornea and offering maximum protection to the stroma.

Other valuable features highlighted by the firm include: the continuous measurement of corneal thickness (using online pachymetry) during the procedure; the particle aspiration system, which removes energy-reducing particles; the Treatment Assistant Manager (TAM), which guides the surgeon through each treatment step; and the unique ergonomics, which optimise the treatment process and contribute to patient comfort.

"With the Schwind AMARIS, we have developed an all-rounder with unmatched high performance, thereby offering an extraordinarily high level of accuracy and safety and the first and only laser to combine all state-of-the-art technologies in one system," enthused Rolf Schwind.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.